Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration

20th June 2014

Pfizer Inc. (NYSE:PFE) and Cellectis (Paris:ALCLS) have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets.

Cellectis’ CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient’s own T-cells to target tumor cells).

Read more at source article www.worldpharmanews.com


Leave a Reply

Your email address will not be published.

6 + 2 =

« back to posts